The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil

Anton, A. M., andD. F. Sayre: The distribution of Dopamine and Dopa in various animals and a method for their determination in diverse biological material. J. Pharmacol. Exp. Therap.145, 326 (1964).

Barbeau, A.: Dopamine and basal ganglia disease. Arch. Neurol.4, 97?102 (1961).

Barbeau, A.: The clinical physiology of side effects in long-term L-Dopa therapy. In: Advances in Neurology, Vol. 5, pp. 347?365. New York: Raven Press. 1974.

Bernheimer, H., W. Birkmayer, andO. Hornykiewicz: Verteilung des 5-Hydroxytryptamines (Serotonin) im Gehirn des Menschen und sein Verhalten bei Patienten mit Parkinson-Syndrom. Klin. Wschr.39, 1056 to 1059 (1961).

Bernheimer, H., W. Birkmayer, andO. Hornykiewicz: Verhalten der Monoaminoxydase im Gehirn des Menschen nach Therapie mit Monoaminoxydase-Hemmern. Wr. klin. Wschr.74 (33/34), 558?559 (1962).

Birkmayer, W., andO. Hornykiewicz: Der L-3, 4-Dioxyphenylalanin (L-Dopa) Effekt bei der Parkinson-Akinese. Wr. klin. Wschr.73, 787?788 (1961).

Birkmayer, W., andO. Hornykiewicz: Der Dioxyphenylalanin (L-Dopa) Effekt beim Parkinson-Syndrom des Menschen. Arch. Psych.203, 560 to 571 (1962).

Birkmayer, W., andE. Neumayer: Die moderne medikamentöse Behandlung des Parkinsonismus. Z. Neurol.202, 257?280 (1972).

Birkmayer, W., W. Danielczyk, E. Neumayer, andP. Riederer: L-Dopa Level in Plasma, Primary Condition for the Kinetic Effect. J. Neural Transm.34, 133?143 (1973).

Birkmayer, W., L. Ambrozi, E. Neumayer, andP. Riederer: Longevity in Parkinson's disease treated with L-Dopa. Clin. Neurol. and Neurosurg.1, 15?19 (1974).

Calne, D. B., L. E. Claveria, andJ. G. Allen: Plasma Levodopa and the ?On-Off? effect. In: Advances in Neurology, Vol. 5, pp. 341?356, New York: Raven Press. 1974.

Carlsson, A., M. Lindqvist, T. Magnusson, andB. Waldeck: On the presence of 3-hydroxytyramine in brain. Science127, 471 (1958).

Coburn, S. P., M. Seidenberg, andR. W. Fuller: Daily rhythm in plasma tyrosine and phenylalanine. P.S.E.B.M.129, 338?343 (1968).

Collins, G. G. S., M. Sandler, E. D. Williams, andM. B. H. Youdim: Multiple forms of human brain mitochondrial monoamine oxidase. Nature225, 817?820 (1970).

Collins, G. G. S., J. Pryse-Davies, M. Sandler, andJ. Southgate: Effect of pretreatment with Oestradiol, Progesterone and Dopa on monoamine oxidase activity in the rat. Nature226, 642?643 (1970 a).

Danielczyk, W.: Die Behandlung von akinetischen Krisen. Med. Welt24, 1278?1282 (1973).

Davison, A. N.: Physiological role of monoamine oxidase. Physiol. Rev.38, 729 (1958).

Duvoisin, R. C.: Variations in the ?On-Off? phenomenon. In: Advances in Neurology, Vol. 5, pp. 339?340. New York: Raven Press. 1974.

Ehringer, H., andO. Hornykiewicz: Verteilung von NA und Dopamin im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wschr.38, 1236?1239 (1960).

Everett, G. M., andR. G. Wiegand: Central amines and behavioural states: a critique and new data. In: Proceedings of the 1st Internat. Pharmacol. Meeting, Vol. 8, Pharmacol. Analysis of central nervous action, pp. 85?92 (Paton, W. D. M., andP. Lindgren, eds.). Oxford: Pergamon Press. 1962.

Fabn, S.: ?On-Off? phenomenon with levodopa therapy in parkinsonism. Neurology 1974, 431?441.

Friedman, A. H., andCh. A. Walker: Circadian rhythms in rat mid-brain and caudate nucleus biogeinc amine levels. J. Physiol.197, 77?85 (1968).

Ganrot, P. O., E. Rosengren, andC. G. Gottfries: Effect of Iproniazid on monoamines and monoamine oxidase in human brain. Experientia1816, 260?261 (1962).

Gey, K. F., A. Pleischer, andW. Burkard: Effect of inhibitors of monoamine oxidase on various enzymes and on the storage of monoamines. Annals of the New York Academy of Sciences107, 1147?1151 (1963).

Hanin, I., R. Massarelli, andE. Costa: Acetylcholine concentrations in rat brain: Diurnal oscillation. Science170 (3955), 341?342 (1970).

Holzbauer, M., andM. B. H. Youdim: Monoamine oxidase and Oestrouscycle. Brit. J. pharmacol.48, 600?608 (1973).

Kraml, M.: A rapid microfluorimetric determination of monoamine oxidase. Biochem. Pharmacol.14, 1648?1685 (1965).

Lloyd, K. G., L. Davidson, andO. Hornykiewicz: Metabolism of Levodopa in the human brain. In: Advances in Neurology, Vol. 3, pp. 173?188. New York: Raven Press. 1973.

Lowry, O. H., N. J. Rosebrough, A. L. Farr, andR. J. Randall: Protein measurement with the Folin phenol reagent. J. Biol. Chem.193, 265?275 (1951).

Markham, C.H.: The ?On-Off? side effect of L-Dopa. In: Advances in Neurology, Vol. 5, pp. 387?396. New York: Raven Press. 1974.

Merck, E.: Klinisches Labor, 11. Aufl., pp. 128?134. Darmstadt: E. Merck. 1970.

Okada, T., T. Fujita, T. Ohta, T. Kato, K. Ikuta, andT. Nagatsu: A 24-hour rhythm in human serum dopamine-?-hydroxylase activity. Experientia30/6, 605?607 (1974).

Papavasiliou, S., G. C. Cotzias, andI. Mena: Short-and long-term approaches to the ?On-Off? phenomenon. In: Advances in Neurology, Vol. 5, pp. 379?386. New York: Raven Press. 1974.

Parvez, H., andS. Parvez: The rate limiting control of enzymes monoamine oxidase and catechol-O-methyl transferase in the foetus and the adult by adreno-cortical hormones. Experientia29, 1259?1262 (1973).

Piepho, R., andA. H. Friedman: Twenty-four hour rhythms in the glycine content of rat hindbrain and spinal cord. Life Sciences10, 1355?1362 (1971).

Quay, W. B.: Differences in circadian rhythms in 5-hydroxy-tryptamine according to brain regions. Am. J. Physiol.215 (6), 1448?1453 (1968).

Riederer, P., W. Birkmayer, E. Neumayer, L. Ambrozi, andW. Linauer: The daily rhythm of HVA, VMA, (VA) and 5-HIAA in depressionsyndrom. J. of Neural Transm.35, 23?45 (1974).

Robinson, D. S., J. M. Davis, A. Nies, C. L. Ravaris, andD. Sylvester: Relation of sex and aging to monoamine oxidase activity of human brain, plasma, and platelets. Arch. Gen. Psychiat.24, 536?539 (1971).

Sandier, M., andM. B. H. Youdim: Monoamine oxidase: the present status. Int. Pharmacopsychiat.9, 27?34 (1974).

Scheving, I., W. H. Harrison, P. Gordon, andJ. E. Pauly: Daily fluctuations (circadian and ultradian) in biogenic amines of the rat brain. American J. Physiol.214 (1), 166?173 (1968).

Sjoerdsma, A., W. Lovenberg, J. A. Oates, J. R. Crout, andS. Udenfriend: Alterations in the pattern of amine excretion in man produced by a monoamine oxidase inhibitor. Science130, 225 (1959).

Spector, S.: Effect of 6-OH-Dopa and L-Dopa on norepinephrine metabolism. In: Monoamines noyaux gris centraux et syndrome de Parkinsons (Symp. Bel-AIR IV, Genève Sept. 1970), pp. 159?163 (de Ajuriaguerra). Genève: G. Gauthier; Paris: Masson.

Spector, S., J. Tarver, andB. Berkowitz: Effects of drugs and physiological factors in the disposition of catecholamines in blood vessels. Pharmacol. Rev.24, 190?202 (1972).

Sweet, R. D., andF. H. McDowell: The ?On-Off? response to chronic L-Dopa treatment of parkinsonism. In: Advances in Neurology, Vol. 5, pp. 331?338. New York: Raven Press. 1974.

Tagliamonte, A., R. Gessa, G. Biggio, L. Vargiu, andG. L. Gessa; Daily changes of free serum tryptophan in humans. Life Sciences14, 349?354 (1974).

Weil-Malherbe, H., H. S. Posner, andG. R. Bowles: Changes in the concentration and intracellular distribution of brain catecholamines: the effects of reserpine,?-phenylisopropylhydrazine, pyrogallol and 3, 4-dihydroxyphenylalanine, alone and in combination. J. Pharm. Exp, Ther.732, 278?286 (1961).

Werder, K. V., G. R. Van Loon, F. Yatsu, andP. H. Forsham: Corticosteroid and growth hormones secretion in patients treated with L-dopa. Klin. Wschr.48, 1454 (1970).

Wurtman, R. J., Ch. Chou, andC. M. Rose: Daily rhythm in tyrosine concentration in human plasma: Persistence on low-protein diets. Science158, 660?662 (1967).

Yahr, M. D.: Variations in the ?On-Off? Effect. In: Advances in Neurology, Vol. 5, pp. 397?404. New York: Raven Press. 1974.

Youdim, M. B. H., andT. L. Sourkes: The effect of heat, inhibitors and riboflavin deficiency on monoamine oxidase. Can. J. Biochem.43, 1305 to 1318 (1965).

Youdim, M. B. H., G. G. S. Collins, M. Sandier, A. B. Bevan Jones, C. M. B. Pare, andW. J. Nicholson: Human brain monoamine oxidase, multiple forms and selective inhibitors. Nature236, 225?228 (1972).

Youdim, M. B. H., M. Holzbauer, andH. F. Woods: Physico-chemical properties, development and regulation of central and peripheral monoamine oxidase activity. In: Neuropsychopharmacology of monoamines and their regulatory enzymes, pp. 11?28. New York: Raven Press. 1974.

Youdim, M. B. H.: Monoamine oxidase: its inhibition. In: Recent Developments in Genetics and Psychopharmacology. Mod. Probl. Pharmacopsych., Vol. 10, pp. 65?88 (Mendlewicz, J., ed.). Basel: Karger. 1975.

Zigmond, M. J., andR. J. Wurtman: Daily rhythm in the accumulation of brain catecholamines synthesized from circulating H3-tyrosine. J. Pharm. Exp. Ther.172 (2), 416?422 (1970).